News & Updates
Filter by Specialty:
Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC
A single tremelimumab regular interval durvalumab (STRIDE) provides survival benefits to Asian patients with unresectable hepatocellular carcinoma (HCC), as shown by the results of the HIMALAYA study.
Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC
28 Jan 2025
Survival benefit with STRIDE for HCC sustained at 5 years
The updated exploratory analysis of the phase III HIMALAYA trial demonstrates a significant overall survival (OS) benefit at 5 years with the STRIDE* regimen comprising tremelimumab and durvalumab for patients with unresectable hepatocellular carcinoma (HCC).
Survival benefit with STRIDE for HCC sustained at 5 years
10 Jan 2025
Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer
The first interim analysis of the phase III LEAP-012 study shows the potential of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) as a new treatment option for intermediate-stage hepatocellular carcinoma (HCC).
Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer
07 Jan 2025
Novel vaccine passes phase II trial in virally suppressed CHB
Therapeutic vaccination with ChAdOx1-HBV/MVA-HBV (VTP-300) has generated CD4+ and CD8+ cells and reduced HBsAg in a subset of chronic hepatitis B (CHB) patients with baseline values <100 IU/ml, as shown in a phase Ib/IIa trial. Moreover, a significant decrease in surface antigen occurs when the vaccine is combined with low-dose nivolumab.
